Cost-effectiveness analysis (CEA) of seven treatment regimens in metastatic hormonesensitive prostate cancer (mHSPC): A public payer perspective using network metaanalysis

被引：0
|
作者：
Kohli, Manish
Dougherty, Maura
Cutshall, Zachary
Beckstead, Rylee
Kohli, Rhea
Haaland, Benjamin
Nelson, Richard
Yoo, Minkyoung
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Univ Utah, Salt Lake City, UT USA
[3] Case Western Reserve Univ, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5081
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.
    Kohli, Manish
    Dougherty, Maura
    Cutshall, Zachary
    Beckstead, Rylee
    Kohli, Rhea
    Haaland, Benjamin
    Nelson, Richard
    Yoo, Minkyoung
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [2] Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective
    Yoo, Minkyoung
    Nelson, Richard E.
    Haaland, Benjamin
    Dougherty, Maura
    Cutshall, Zachary A.
    Kohli, Rhea
    Beckstead, Rylee
    Kohli, Manish
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (11): : 1374 - 1382
  • [3] Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective
    Yoo, Minkyoung
    Nelson, Richard E.
    Cutshall, Zachary
    Dougherty, Maura
    Kohli, Manish
    JCO ONCOLOGY PRACTICE, 2023, 19 (03) : 149 - +
  • [4] Cost-effectiveness Analysis of Triptorelin, Goserelin, and Leuprolide in the Treatment of Patients with Metastatic Prostate Cancer: A Societal Perspective
    Rezaee, Mehdi
    Karimzadeh, Iman
    Hashemi-Meshkini, Amir
    Zeighami, Shahryar
    Bazyar, Mohammad
    Lotfi, Farhad
    Keshavarz, Khosro
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 42
  • [5] Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy
    Iannazzo, S.
    Pradelli, L.
    Carsi, M.
    Perachino, M.
    VALUE IN HEALTH, 2011, 14 (01) : 80 - 89
  • [6] Adherence to standard of care (SOC) therapy for the treatment of metastatic hormonesensitive prostate cancer (mHSPC): A single-institution analysis.
    Dhillon, Puneet
    Ornstein, Moshe Chaim
    Gupta, Shilpa
    Nizam, Amanda
    Gilligan, Timothy D.
    Martin, Allison
    Bonham, Amanda
    Maroli, Kimberly
    Wee, Christopher Eing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] Cost-effectiveness analysis of additional local prostate radio therapy in metastatic prostate cancer from a medicare perspective
    Kramer, Kristina K. M.
    Schmidt-Hegemann, Nina-Sophie
    Westhofen, Thilo
    Foglar, Marco
    Ricke, Jens
    Westphalen, C. Benedikt
    Unterrainer, Marcus
    Kunz, Wolfgang G.
    Mehrens, Dirk
    RADIATION ONCOLOGY, 2024, 19 (01)
  • [8] BEVACIZUMAB FOR THE TREATMENT OF METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS
    Fortune-Greeley, A.
    Cornell, P.
    VALUE IN HEALTH, 2010, 13 (03) : A34 - A34
  • [9] A RETROSPECTIVE ANALYSIS OF THE COST-EFFECTIVENESS OF TREATMENT WITH METASTRON IN PATIENTS WITH PROSTATE-CANCER METASTATIC TO BONE
    MCEWAN, AJB
    AMYOTTE, GA
    MCGOWAN, DG
    MACGILLIVRAY, JA
    PORTER, AT
    EUROPEAN UROLOGY, 1994, 26 : 26 - 31
  • [10] A COST-EFFECTIVENESS ANALYSIS (CEA) FOR DENOSUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY FOR CANCER TREATMENT-INDUCED BONE LOSS (CTIBL) IN NON-METASTATIC PROSTATE CANCER (PRCA): A SWEDISH PERSPECTIVE
    Shroff, S.
    Martin, M.
    Kearney, M.
    Lothgren, M.
    Bracco, A.
    VALUE IN HEALTH, 2010, 13 (07) : A266 - A267
12345